# Neurogene Inc. Common Stock (NGNE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $38.60, market value $772 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Neurogene Inc. Common Stock reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -11.4%** (5-yr avg -76.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -34.1%**. Return on equity is negative because earnings are negative.
- **Return on assets: -31.3%**. Each dollar of assets produces -31.3% of profit.

## Growth
- **Revenue growth (1 yr): -100.0%**. Revenue fell 100.0% over the last year.
- **EPS growth (1 yr): 0.9%**. Earnings per share rose 0.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 16.56** (quick 16.56). Current assets cover the next year's liabilities 16.56 times.
- **Altman Z-score: 20.71**. A Z-score of 20.71 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Neurogene Inc. Common Stock does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 96.8%** (YTD 87.4%, 3-mo 45.7%). The shares are up 96.8% over twelve months including dividends.
- **From 52-week high: -11.6%** (142.3% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.50** (volatility 83%). Beta of 1.50 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NGNE · Page: https://foliofundamentals.com/stocks/ngne

Not investment advice.